JP2021504384A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021504384A5 JP2021504384A5 JP2020529159A JP2020529159A JP2021504384A5 JP 2021504384 A5 JP2021504384 A5 JP 2021504384A5 JP 2020529159 A JP2020529159 A JP 2020529159A JP 2020529159 A JP2020529159 A JP 2020529159A JP 2021504384 A5 JP2021504384 A5 JP 2021504384A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- pharmaceutical composition
- amide
- composition according
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 230000035772 mutation Effects 0.000 claims description 14
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 claims description 11
- 102100038595 Estrogen receptor Human genes 0.000 claims description 10
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- OAWXZFGKDDFTGS-BYPYZUCNSA-N (2s)-pyrrolidine-1,2-dicarboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(O)=O OAWXZFGKDDFTGS-BYPYZUCNSA-N 0.000 claims description 9
- SJXNPGGVGZXKKI-NYYWCZLTSA-N (E)-3-[4-[[2-[2-(1,1-difluoroethyl)-4-fluorophenyl]-6-hydroxy-1-benzothiophen-3-yl]oxy]phenyl]prop-2-enoic acid Chemical compound FC(C)(F)C1=C(C=CC(=C1)F)C1=C(C2=C(S1)C=C(C=C2)O)OC1=CC=C(C=C1)/C=C/C(=O)O SJXNPGGVGZXKKI-NYYWCZLTSA-N 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 7
- -1 2,2,2-trifluoro-1,1-dimethyl-ethyl Chemical group 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 238000000034 method Methods 0.000 description 10
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 229940127557 pharmaceutical product Drugs 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762593760P | 2017-12-01 | 2017-12-01 | |
| US62/593,760 | 2017-12-01 | ||
| US201862771757P | 2018-11-27 | 2018-11-27 | |
| US62/771,757 | 2018-11-27 | ||
| PCT/IB2018/059470 WO2019106604A1 (en) | 2017-12-01 | 2018-11-29 | Pharmaceutical combination comprising lsz102 and alpelisib |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021504384A JP2021504384A (ja) | 2021-02-15 |
| JP2021504384A5 true JP2021504384A5 (enExample) | 2022-01-06 |
Family
ID=64901034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020529159A Pending JP2021504384A (ja) | 2017-12-01 | 2018-11-29 | Ｌｓｚ１０２及びアルペリシブを含む医薬品の組合せ |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10695333B2 (enExample) |
| EP (1) | EP3716969A1 (enExample) |
| JP (1) | JP2021504384A (enExample) |
| CN (1) | CN111386113A (enExample) |
| TW (1) | TW201924675A (enExample) |
| WO (1) | WO2019106604A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11179365B2 (en) | 2017-11-16 | 2021-11-23 | Novartis Ag | Pharmaceutical combination comprising LSZ102 and ribociclib |
| DK3847157T3 (da) | 2018-09-07 | 2022-08-08 | Sanofi Sa | Fremgangsmåde til fremstilling af methyl-[6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylat] og salt deraf |
| EP3849545A1 (en) * | 2018-09-10 | 2021-07-21 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of neurofibromatosis |
| WO2021063967A1 (en) | 2019-10-01 | 2021-04-08 | Sanofi | Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof |
| CA3160897A1 (en) | 2019-12-09 | 2021-06-17 | Sanofi | Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative |
| TW202146007A (zh) | 2020-02-27 | 2021-12-16 | 法商賽諾菲公司 | 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合 |
| IL302153B1 (en) | 2020-10-19 | 2026-07-01 | Sanofi Sa | 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES |
| IL302152B1 (en) | 2020-10-19 | 2026-07-01 | Sanofi Sa | 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2618489A1 (en) | 2005-09-07 | 2007-03-15 | Laboratoires Serono S.A. | Pi3k inhibitors for the treatment of endometriosis |
| UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| EP2650401A1 (de) | 2012-04-10 | 2013-10-16 | Siemens Aktiengesellschaft | Kraftwerk basiertes Methanisierungssystem |
| NZ710385A (en) * | 2013-02-19 | 2016-10-28 | Novartis Ag | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders |
| EA031077B1 (ru) * | 2013-06-19 | 2018-11-30 | Серагон Фармасьютикалз, Инк. | Модулятор рецептора эстрогена и его применения |
| EP4772247A2 (en) | 2013-08-14 | 2026-07-08 | Novartis AG | Combination therapy comprising ribociclib and fulvestrant for the treatment of cancer |
| WO2015028409A1 (de) | 2013-08-27 | 2015-03-05 | Bayer Pharma Aktiengesellschaft | 6,7-dihydro-5h-benzo[7]annulen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln |
| JP6223154B2 (ja) | 2013-11-29 | 2017-11-01 | ロッテ アドバンスト マテリアルズ カンパニー リミテッド | ポリアミド樹脂およびその製造方法 |
| SG11201607334YA (en) | 2014-03-13 | 2016-10-28 | Hoffmann La Roche | Therapeutic combinations with estrogen receptor modulators |
| MX384605B (es) | 2015-04-29 | 2025-03-14 | Radius Pharmaceuticals Inc | Combinación de palbociclib y rad1901 para usarse en el tratamiento de cáncer de mama en un sujeto con cáncer positivo a receptor de estrógeno. |
| AU2016287189A1 (en) * | 2015-06-29 | 2017-10-12 | F. Hoffmann-La Roche Ag | Methods of treatment with taselisib |
| CN108472289A (zh) * | 2015-11-02 | 2018-08-31 | 诺华股份有限公司 | 磷脂酰肌醇3-激酶抑制剂的给药方案 |
| JP7084875B2 (ja) * | 2016-03-29 | 2022-06-15 | ノバルティス アーゲー | 水－界面活性剤混合物を含む反応媒体 |
| JP7229162B2 (ja) | 2017-01-06 | 2023-02-27 | ジー１ セラピューティクス， インコーポレイテッド | 癌の治療に対する併用療法 |
| US11179365B2 (en) * | 2017-11-16 | 2021-11-23 | Novartis Ag | Pharmaceutical combination comprising LSZ102 and ribociclib |
-
2018
- 2018-11-29 WO PCT/IB2018/059470 patent/WO2019106604A1/en not_active Ceased
- 2018-11-29 EP EP18826816.3A patent/EP3716969A1/en not_active Withdrawn
- 2018-11-29 CN CN201880076600.2A patent/CN111386113A/zh active Pending
- 2018-11-29 JP JP2020529159A patent/JP2021504384A/ja active Pending
- 2018-11-29 US US16/204,471 patent/US10695333B2/en not_active Expired - Fee Related
- 2018-12-03 TW TW107143297A patent/TW201924675A/zh unknown
-
2020
- 2020-05-07 US US16/869,450 patent/US20210000810A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6141958B2 (ja) | 増殖性疾患の治療のための併用療法（ベムラフェニブ及びｍｄｍ２阻害剤） | |
| TWI314868B (en) | Pharmaceutical preparation containining 5-methyl-1-phenyl-2-(1h)-pyridone as an active ingredient | |
| BR112020006039A2 (pt) | formulações de niraparibe | |
| JP2020512337A5 (enExample) | ||
| JP2015510916A5 (enExample) | ||
| JP2022536687A5 (enExample) | ||
| AR045289A1 (es) | Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento | |
| JP2015517523A5 (enExample) | ||
| JP2022508513A5 (enExample) | ||
| JP2021532193A5 (enExample) | ||
| JP2024502446A5 (enExample) | ||
| JP6181044B2 (ja) | カプセル剤 | |
| JP2021503448A5 (enExample) | ||
| JP2022177119A5 (enExample) | ||
| JP2013536206A5 (enExample) | ||
| IL272834B2 (en) | Amantadine compositions, preparations thereof, and methods of use | |
| JP7854206B2 (ja) | 肺線維症の予防または治療用の薬学製剤 | |
| WO2012080703A1 (en) | Pharmaceutical composition comprising imatinib | |
| CN113557016A (zh) | 衣壳组装调节剂固体配制品 | |
| CN115607545B (zh) | 依达拉奉在自闭症谱系障碍治疗中的应用 | |
| WO2007140555A1 (en) | Pharmaceutical composition comprising cyclobenzaprine and aceclofenac in association | |
| CN117618436A (zh) | 一种稠环嘧啶类化合物的用途 | |
| JP2021091608A5 (enExample) | ||
| JP2015515971A5 (enExample) | ||
| ES3059301T3 (en) | Sustained release compositions of 4-aminopyridine |